Practice-Changing Research on Prostate Cancer Presented at ASCO 2012: With Commentary by Dr Neal Shore
This article reviews the most significant research on prostate cancer presented last month at ASCO 2012, with commentary from Dr Neal Shore.
This article reviews the most significant research on prostate cancer presented last month at ASCO 2012, with commentary from Dr Neal Shore.
Abiraterone acetate (AA) plus prednisone (P) produced a statistically significant improvement in radiographic progression-free survival (rPFS) and a strong trend for increased overall survival (OS), according to the results of a study presented by a multinational team of researchers at the 2012 American Society of Clinical Oncology Annual Meeting.
Dr. Barbara Burtness is a physician-scientist of the Fox Chase Cancer Center and an expert in the treatment of head and neck cancer.
Maintenance chemotherapy with the combination of gemcitabine and paclitaxel (GP) following clinical response to GP is associated with improved survival times.
Neither weekly nab-paclitaxel nor ixabepilone are superior to weekly paclitaxel in patients with chemotherapy-naïve advanced breast cancer receiving bevacizumab.
Daily duloxetine therapy effective and well-tolerated for the treatment of CIPN.
Radium-223 chloride therapy significantly prolongs median OS time for men with castration-resistant prostate cancer (CRPC) bone metastasis.
Adding weekly paclitaxel to adjuvant FAC therapy offers a modest improvement in disease-free survival for patients with high-risk, node-negative breast cancer.
Crizotinib has a strong response rate, progression-free survival (PFS), and is well tolerated in patients with ALK-positive non-small cell lung cancer (NSCLC).
First-line gefitinib for advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation offers survival benefit.